(Reuters) - Swiss drugmaker Roche said on Monday it had started late-stage trials for its experimental drug lampalizumab as a treatment for a serious eye disease.
The Basel-based firm has initiated Phase III trials for lampalizumab as a treatment for geographic atrophy, a leading cause of blindness in adults over 55, which gradually causes vision loss in the macula, making it harder to read, drive and recognise people’s faces.
Help employers find you! Check out all the jobs and post your resume.
